C4 Therapeutics logo
C4 Therapeutics
CCCC | NASDAQ
Chart Builder DCF Calculator
$2.65
-$0.11 (-3.99%)
At close: Nov 16, 2026, 4:00 PM ET
$2.68
+$0.03 (+1.24%)
After-hours: Nov 16, 2026, 7:58 PM ET

C4 Therapeutics Company Profile

Company profile explained

Company Profile

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses. The company's primary drug candidate, CFT7455, is an orally administered MonoDAC degrader of the IKZF1 and IKZF3 proteins. This compound is currently undergoing Phase 1/2 clinical trials for the treatment of multiple myeloma and various non-Hodgkin lymphomas, such as peripheral T-cell lymphoma and mantle cell lymphoma. Additionally, C4 Therapeutics is advancing several other programs: CFT8634, an orally bioavailable BiDAC degrader targeting the BRD9 protein, for potential use in synovial sarcoma and SMARCB1-deleted solid tumors. CFT1946, an orally administered BiDAC degrader designed to act on the V600X mutant BRAF, aimed at indications like melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies. CFT8919, an orally available, allosteric, and mutant-selective BiDAC degrader specifically targeting epidermal growth factor receptor (EGFR) with an L858R mutation in NSCLC. Their early-stage pipeline also features RET degraders for various forms of cancer. C4 Therapeutics, Inc. has formed strategic partnerships with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. The company was established in 2015 and its headquarters are located in Watertown, Massachusetts.

Key Executives

Name Position
Andrew J. Hirsch Chief Executive Officer, President & Director
Kelly Schick Chief People Officer
Christopher Nasveschuk Senior Vice President of Chemistry
Courtney Solberg Senior Manager of Investor Relations
Isabel Chiu Senior Vice President of Strategic Alliances & Business Development
Kendra Adams Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer
Kenneth C. Anderson Co-Founder, Independent Director & Member of Scientific Advisory Board
Leonard J. Reyno Chief Medical Officer
Nathanael S. Gray Co-Founder & Member of Scientific Advisory Board
Roy Pollock Senior Vice President of Biological Sciences

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 25, 2026 8-K Current Report
Sep 21, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 12, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 8-K Current Report
View All SEC Filings ➞
C4 Therapeutics
C4 Therapeutics logo
Country United States
IPO Date Oct 2, 2020
Industry Biotechnology
Sector Healthcare
Employees 104
CEO Andrew J. Hirsch

Contact Details

490 Arsenal Way Watertown, Massachusetts 02472 United States

Stock Details

Ticker Symbol CCCC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001662579
CUSIP Number 12529R107
ISIN Number US12529R1077
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.